时珍国医国药2026，Vol.37Issue(13)：2586-2591,6.DOI:10.70976/j.1008-0805.SZGYGY-2026-1326
参附方治疗心血管系统疾病的研究进展
Research progress on the treatment of cardiovascular diseases with Shenfu Formula(参附方)
摘要
Abstract
The prevalence of cardiovascular system diseases is continuously increasing,posing serious threats to patients'health and quality of life.Recent clinical trial results have demonstrated that the Shenfu Formula(参附方,SFF)is highly effective in treating car-diovascular system diseases,often used in combination with Western medicine or as a combined formula to address conditions such as heart failure and shock.This article integrates clinical and basic research to summarize the clinical and mechanistic studies of the SFF in treating cardiovascular system diseases,offering new insights and approaches for the prevention and treatment of these conditions with traditional Chinese medicine Tap.关键词
参附方/心血管系统疾病/心肌细胞凋亡/休克Key words
Shenfu(参附方)/Cardiovascular diseases/Cardiomyocyte apoptosis/Shock分类
医药卫生引用本文复制引用
陈程,张杼惠,李继庭,余林德,黄咏歌,何汝州,詹汉生..参附方治疗心血管系统疾病的研究进展[J].时珍国医国药,2026,37(13):2586-2591,6.基金项目
广东省中医药局科研面上项目(20241011) （20241011）
广东省第二中医院科研创新基金基础与应用基础研究青年启航项目(SEZYY2023A16) （SEZYY2023A16）
广东省第二中医院"青年培优计划"人才项目(2025年) （2025年）
湖南中医药大学校院联合基金一般项目(2023XYLH020) （2023XYLH020）
